| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8e0db8a6ad24e2cb1eba78ebf4dffcd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 |
| filingDate |
2015-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfb2333d6d3a7a78caaf4488c58fc8f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4ae2f7b8de0396aeabc66554befdb60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01cafbea8f7061a8a81eac6da57f403b |
| publicationDate |
2015-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015161255-A1 |
| titleOfInvention |
Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy |
| abstract |
Disclosed herein are methods of treating and diagnosing muscular dystrophy. In some examples, the methods include treating muscular dystrophy by administering to the subject a therapeutically effective amount of an agent that alters the expression of at least one miR gene product, such as miRNA-124 and/or miRNA-29 thereby treating muscular dystrophy. In one particular example, the method of treatment includes administering an agent that decreases the expression or activity of miRNA-124. In another embodiment, the method of treatment includes administering a composition that includes one or more agents to decrease the expression and/or activity of miRNA-124 and one or more agents to alter the activity of miRNA-29 (increase or decrease). Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017181014-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7189771-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3598978-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11723986-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11534501-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022192749-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11406717-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11298429-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020020857-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019513779-A |
| priorityDate |
2014-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |